BMI ‐dependent prognostic role of EEF1G in breast cancer: A 15‐year follow‐up of the Guangzhou Breast Cancer Cohort Study
Rattachement africain : cn, gb, hk. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
Abstract Objective Eukaryotic elongation factor 1 gamma (EEF1G) has emerged as a potential prognostic marker in various malignancies. Yet, its association with breast cancer (BC) prognosis, particularly in the context of body mass index (BMI) status, remains unexplored. Therefore, we investigated the prognostic value and role of EEF1G in BC across different BMI categories. Methods EEF1G expression was assessed through immunohistochemistry in tissue microarrays on 1011 patients with primary invasive BC. Prognostic effects were analyzed using the Cox proportional hazards regression. GSE78958 dataset downloaded from the Gene Expression Omnibus (GEO) database was used to validate our findings. Gene Set Enrichment Analysis (GSEA) was performed using R packages, and protein–protein interaction (PPI) networks were generated using the STRING database and Cytoscape software. Results Elevated EEF1G expression was associated with a better prognosis in patients with BMI ≤ 24 kg/m 2 (hazard ratio (HR) for overall mortality = 0.67, 95% confidence interval (CI): 0.43–1.03; HR for progression = 0.60, 95% CI: 0.42–0.86). In contrast, for patients with BMI > 24 kg/m 2 , it appeared to be associated with poorer outcomes (HR for overall mortality = 1.74, 95% CI: 0.96–3.17; HR for progression = 1.63, 95% CI: 1.00–2.66). In patients with BMI > 24 kg/m 2 , EEF1G was associated with specific metabolic and oncogenic pathways, which were not statistically significant in patients with BMI ≤ 24 kg/m 2 . The top interacting genes with EEF1G differed between the BMI categories. Conclusions This study showed EEF1G expression was inversely associated with BC prognosis in different BMI categories, indicating its potential as a prognostic marker and therapeutic target in BC. The differential effects underscore the need for personalized approaches in BC management and research.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé, mais le titre doit être comparé manuellement.
- Titre Crossref
- <scp>BMI</scp> ‐dependent prognostic role of <scp>EEF1G</scp> in breast cancer: A 15‐year follow‐up of the Guangzhou Breast Cancer Cohort Study
- Date Crossref
- 01/09/2025
- Éditeur
- Wiley
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Sun Yat-sen University The Third Affiliated Hospital pays non établi dans la noticeUniversité ou école supérieure
-
Sun Yat-sen University Cancer Center pays non établi dans la noticeÉtablissement de santé
-
Third Affiliated Hospital of Sun Yat-sen University pays non établi dans la noticeÉtablissement de santé
-
University of Birmingham Institute of Applied Health Research pays non établi dans la noticeUniversité ou école supérieure
-
University of Hong Kong pays non établi dans la noticeUniversité ou école supérieure
-
School of Public Health Sun Yat‐sen University Guangzhou China pays non établi dans la noticeUniversité ou école supérieure
-
The Sun Yat‐Sen University Cancer Center Guangzhou China pays non établi dans la noticeUniversité ou école supérieure
-
The Third Affiliated Hospital Sun Yat‐Sen University Guangzhou China pays non établi dans la noticeUniversité ou école supérieure
The Third Affiliated Hospital — Sun Yat-sen University, Sun Yat-sen University Cancer Center et Third Affiliated Hospital of Sun Yat-sen University, avec 5 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.